source
- FDA releases proposed commitment letter detailing changes to GDUFA IV programThe U.S. Food and Drug Administration has issued a proposed commitment letter for the fourth reauthorization of the Generic Drug User Fee Amendments (GDUFA IV). The letter follows several months o…
- Definium's LSD-based therapy shows strong Phase 3 results in generalized anxiety disorderDefinium Therapeutics reported that its LSD-derived oral tablet, DT120, met its primary endpoint in a Phase 3 trial for generalized anxiety disorder. The study enrolled over 200 participants and co…